Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05
Authors' conclusion
This exploratory analysis showed that fracture incidence on ALN was constant regardless of renal function. It also suggested that the incidence of vertebral fractures on TPTD-ALN was lower than ALN monotherapy in CKD 1/2 patients.
Study context
- Population
- Elderly Japanese women at high fracture risk in JOINT-05; subgroups by baseline chronic kidney disease (CKD): CKD 1/2 (estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m²), CKD 3a (eGFR 45–59), CKD 3b/4 (eGFR < 45)
- Participants
- 483 vs 496
- Comparison
- Once-weekly TPTD for 72 weeks followed by alendronate (ALN) for 48 weeks vs ALN monotherapy for 120 weeks
- TPTD-ALNn = 483
- ALNn = 496reference
- Primary endpoint
- Incidences of vertebral fractures including morphometric fractures, non-vertebral fractures and all fractures, by baseline CKD stage
Methodological detailsexploratory subgroup analysis, subgroups by baseline CKD status (eGFR)
- Exploratory subgroup analysis
- Subgroups by baseline CKD status (eGFR)
Primary result
As reported in the abstract
Vertebral fractures in CKD 1/2 (N = 556; 90 morphometric vertebral fractures)
- Non-vertebral fractures in CKD 3b/4 (N = 112; 10 non-vertebral fractures): incidence lower with ALN than TPTD-ALN, although the number of fractures was small
- In ALN, incidences of vertebral, non-vertebral and all fractures constant across CKD stages
- TPTD-ALN vs ALN: P = 0.01
- Exploratory subgroup analysis
Further findings
Baseline associations
- Higher CKD stages associated with age and number of prevalent vertebral fractures
Original publication
Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. Published 30 September 2024. doi:10. 1007/ s00198-024-07260-9
Composed by AI from the published abstract and checked against it. How Briefs are made →